California
Biotech Insights
February 17, 2026
Recent Funding: Evommune (SF) Raises ~$125M in Private Placement to Advance Inflammatory Disease Pipeline Evommune announced a $125 million private placement, selling ~4.5M shares at $27.88 per share to new and existing healthcare-focused institutional investors, with the financing expected to close in mid-February 2026. The proceeds will be used to advance its clinical-stage programs in […]
February 10, 2026
Recent Funding: Angitia Biopharmaceuticals (LA) Raises $130M Series D to Advance Bone and Musculoskeletal Biologics Angitia raised $130 million in a Series D led by Frazier Life Sciences and Venrock to support three biologic drug candidates in clinical testing for osteoporosis, brittle bone disease, and degenerative disc disease, bringing total funding to $454 million.Its pipeline […]
February 3, 2026
Recent Funding: TRexBio (SF) Raises Additional $50M to Advance Regulatory T Cell Therapies TRexBio extended its Series B by $50 million, bringing total Series B funding to $134 million, to advance its lead drug TRB-061, now in a Phase 1a/b trial for inflammatory diseases, with an initial focus on atopic dermatitis. The new capital gives […]
January 29, 2026
January 27, 2026
Recent Funding: Mendra (SF) Launches with $82M Series A to Acquire and Commercialize Rare Disease Drugs Mendra raised $82M in a Series A co-led by OrbiMed, 8VC, and 5AM Ventures to identify and acquire underappreciated rare disease medicines that are already post–proof-of-concept or near commercialization. Led by former BioMarin executive Joshua Grass, Mendra plans to […]
January 20, 2026
Recent Funding: Soley Therapeutics (SF) Raises $200M Series C to Advance Stress-Response Drug Platform Soley Therapeutics emerged from stealth with a $200M Series C, bringing total funding to $290M, to advance a drug discovery platform designed to control how cells respond to biological stress – with applications across cancer, obesity, hair loss, and neurodegenerative diseases. […]